Writing informed consent forms patients actually understand

Informed consent is supposed to protect patients. It’s the document that explains what a clinical trial involves, what the risks are, and what participants are agreeing to. In practice, most ICFs (Informed Consent Forms) protect the sponsor’s legal department more than they inform the patient.

In our experience, most ICFs read at a college level, while IRBs and plain-language guidance ask for something closer to a middle school reading level. That gap isn’t just a readability problem. It’s an ethical one.

Here’s how to write consent forms that actually work.

Why ICFs are hard to read

The informed consent form serves multiple masters. It needs to satisfy FDA regulations (21 CFR 50.25), ICH-GCP (International Council for Harmonisation Good Clinical Practice) guidelines, the site’s IRB, the sponsor’s legal team, and the patient.

Each of those stakeholders adds language. The FDA requires specific elements. Legal adds indemnification clauses. The IRB wants additional disclosures about local resources. The medical monitor insists on detailed pharmacokinetic descriptions.

Nobody removes anything. The document grows.

By the time a patient sees it, the ICF is 25 pages of dense text, written in passive voice, full of medical terminology, and organized around regulatory requirements instead of patient questions.

Common readability problems:

• Sentences that run 40+ words
• Medical terms used without definition (“randomization,” “pharmacokinetics,” “dose-limiting toxicity”)
• Passive voice throughout (“You will be randomized” instead of “We will assign you to a treatment group by chance, like flipping a coin”)
• Risk sections that list every possible adverse event without context on likelihood
• Legalistic phrasing that obscures meaning (“In the event of a research-related injury, reasonable medical care will be made available” tells the patient almost nothing useful)

What plain language actually means

Plain language doesn’t mean dumbing things down. It means organizing information the way patients think about it and using words they already know.

The core principles:

• Use short sentences. Aim for 15 to 20 words per sentence on average.
• Define every technical term when you first use it. “Placebo (a treatment that looks like the study drug but has no active medicine)” works fine.
• Use active voice. “We will draw your blood” is clearer than “Blood samples will be obtained.”
• Organize sections around patient questions: “What will happen to me?” “What are the risks?” “Can I stop participating?”
• Use headers, bullets, and white space. A wall of text is not a consent form, it’s a barrier to consent.

Practical tips for improving readability:

• Run every draft through a readability tool. Flesch-Kincaid is the standard. Target a score that corresponds to 6th through 8th grade reading level.
• Read the document out loud. If a sentence doesn’t sound like something you’d say to a patient in a clinic visit, rewrite it.
• Include a study summary at the top. One page. What the study is about, what participation involves, how long it lasts, and the main risks. Give patients the big picture before the details.
• Use tables for visit schedules and procedures. A table showing “Visit 1: blood draw, physical exam, questionnaire” is faster to understand than three paragraphs describing the same information.

How site-specific negotiation works

The sponsor writes a template ICF. Then every site customizes it. This is where things get complicated.

Each site’s IRB has its own requirements. Some require specific language about emergency contacts. Others mandate state-specific disclosures about genetic testing or pregnancy. Some add boilerplate about patient rights that the sponsor’s template doesn’t include.

Sites also modify the language based on their patient population. A community hospital serving a predominantly non-English-speaking population has different needs than a university research center.

Where negotiations stall:

• Sites adding language that changes the risk/benefit description in ways the sponsor’s medical team won’t accept
• IRBs requiring removal of sponsor-mandated language
• Disagreements about compensation descriptions
• Translation requirements for non-English-speaking participants

How to keep it moving:

• Include a “site-specific” section in your template with clear markers for where local modifications belong. This prevents sites from editing the core consent language.
• Provide a list of acceptable and unacceptable modifications upfront. Sites shouldn’t have to guess which changes will get rejected.
• Build your template with common state-specific requirements already addressed. If you know you’re opening sites in California, plan for the Experimental Subject’s Bill of Rights (California Health and Safety Code section 24172) from the start, so sites aren’t adding it after the sponsor’s review is finished.
• Set a maximum turnaround time for consent reviews. Two rounds of comments should be enough if the template is well-constructed.

Harmonizing across multi-site trials

A global trial with 50 sites can end up with 50 different consent forms. That creates real problems for data integrity, regulatory inspections, and protocol compliance.

The goal isn’t identical consent forms at every site. That’s not realistic or appropriate. The goal is consistency in the core content while allowing legitimate local variation.

How to do it:

• Maintain a master ICF with version control. Every site-specific version should reference the master version number.
• Use a consent matrix that tracks which sections are locked (cannot be modified) versus flexible (can be adapted for local requirements).
• Assign one person to review all site-specific modifications. This prevents contradictions between sites.
• When amendments happen, update the master first and distribute a clear change summary. Don’t make sites figure out what changed by comparing two 25-page documents.

Handling translations

Translated consent forms need more than word-for-word translation. They need cultural adaptation. Medical concepts don’t always translate directly, and reading levels vary across languages.

• Use certified medical translators, not bilingual staff
• Back-translate every translated consent to verify accuracy
• Have a native speaker from the target patient population review the translation for clarity, not just accuracy
• Budget time for translations in your startup timeline. In our experience, a translated ICF reviewed by several stakeholders takes several weeks.

A practical next step

Start with your current ICF template. Run it through a readability checker. If it scores above an 8th grade reading level, you have work to do.

Pick the three longest sentences and rewrite them. Replace passive voice with active voice. Define every technical term. Add a one-page summary at the top.

Then ask yourself: if a patient read only the first two pages, would they understand what they’re signing up for? If the answer is no, that’s where to focus.

Once the template is in better shape, bring the site-specific section and the consent matrix into the same revision. Readability work done on the master alone gets undone site by site unless the negotiation process protects it, and that is where most of the consent effort in a multi-site trial actually goes.